Giovanna Macanhã Scremin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Giovanna Macanhã Scremin has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Pedro Bicudo Bregion
State University of Campinas, Campinas, Brazil
6 shared publications - Victor Kenzo Ivano
State University of Campinas, Campinas, Brazil
6 shared publications - Everton Cazzo
State University of Campinas, Campinas, Brazil
5 shared publications - Leonardo Halamy Pereira
Fluminense Federal University, Niteroi, Brazil
5 shared publications - Gabriel José Souto Maior de França
Federal University of Pernambuco, Recife, Brazil
4 shared publications - João Gabriel Romero Braga
Fundação Padre Albino, Catanduva, Brazil
4 shared publications
Latest Publications
- Open Access
- 22 September 2026
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (10) , 5528-5542
Erector Spinae Block in Bariatric Surgery: a Systematic Review and Meta-Analysis of Randomized Controlled Trials
Introduction: Obesity is a growing global health issue, and bariatric surgery offers effective weight loss outcomes. Postoperative pain management remains a challenge, with multimodal analgesia and regional blocks like the erector spinae plane (ESPB) showing promise. This review aims to evaluate the efficacy of the Erector Spinae Plane Block (ESPB) on key postoperative outcomes in bariatric surgery, specifically its impact on opioid consumption, pain management, and complication rates. Methods: We conducted a systematic review and meta-analysis following PRISMA guidelines. In January 2025, we conducted a comprehensive search across PubMed, Embase, and Cochrane databases for studies comparing erector spinae block in bariatric surgery. Data extraction was standardized, focusing on postoperative analgesic consumption, pain control, intraoperative opioid consumption, respiratory complications and PONV. Statistical analysis was performed using RevMan 9.0.0, with random-effects models. Heterogeneity was assessed using Cochran’s Q test and I² statistic. Results: The analysis included 9 randomized controlled trials (RCTs) with a total of 553 patients. ESP block significantly reduced total opioid consumption (MD -9.53, 95% CI -15.10 to -3.96, p = 0.0008), pain scores like NRS (MD -1.15, 95% CI -1.76 to -0.55, p = 0.0002). Despite heterogeneity across studies, ESPB was associated with reduced opioid use and better pain control. ESP block was associated with a significant reduction in VAS pain scores during the first 12 h after surgery, although substantial heterogeneity was observed across studies. Using the ESP block significantly reduced the incidence of postoperative nausea and vomiting, with consistent results across studies (I² = 0%). There was no significant difference in the incidence of respiratory complications between the study groups. Conclusion: ESPB is associated with significant reductions in postoperative pain scores and total opioid consumption, while no significant difference in respiratory complications was observed between the groups.
- 22 September 2026
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (10) , 5528-5542
Open AccessErector Spinae Block in Bariatric Surgery: a Systematic Review and Meta-Analysis of Randomized Controlled Trials
Introduction: Obesity is a growing global health issue, and bariatric surgery offers effective weight loss outcomes. Postoperative pain management remains a challenge, with multimodal analgesia and regional blocks like the erector spinae plane (ESPB) showing promise. This review aims to evaluate the efficacy of the Erector Spinae Plane Block (ESPB) on key postoperative outcomes in bariatric surgery, specifically its impact on opioid consumption, pain management, and complication rates. Methods: We conducted a systematic review and meta-analysis following PRISMA guidelines. In January 2025, we conducted a comprehensive search across PubMed, Embase, and Cochrane databases for studies comparing erector spinae block in bariatric surgery. Data extraction was standardized, focusing on postoperative analgesic consumption, pain control, intraoperative opioid consumption, respiratory complications and PONV. Statistical analysis was performed using RevMan 9.0.0, with random-effects models. Heterogeneity was assessed using Cochran’s Q test and I² statistic. Results: The analysis included 9 randomized controlled trials (RCTs) with a total of 553 patients. ESP block significantly reduced total opioid consumption (MD -9.53, 95% CI -15.10 to -3.96, p = 0.0008), pain scores like NRS (MD -1.15, 95% CI -1.76 to -0.55, p = 0.0002). Despite heterogeneity across studies, ESPB was associated with reduced opioid use and better pain control. ESP block was associated with a significant reduction in VAS pain scores during the first 12 h after surgery, although substantial heterogeneity was observed across studies. Using the ESP block significantly reduced the incidence of postoperative nausea and vomiting, with consistent results across studies (I² = 0%). There was no significant difference in the incidence of respiratory complications between the study groups. Conclusion: ESPB is associated with significant reductions in postoperative pain scores and total opioid consumption, while no significant difference in respiratory complications was observed between the groups.
- Open Access
- 19 March 2026
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (4) , 1946-1954
Hormone PYY does not Explain the Variability in Weight Loss After Roux-en-Y Gastric Bypass: Evidence From a Meta-Analysis.
Background: Peptide YY (PYY) plays a key role in postprandial satiety and is markedly increased after Roux-en-Y gastric bypass (RYGB). While GLP-1 has been widely studied, the role of PYY as a predictor of weight loss success remains unclear. Some patients are considered non-responders, achieving < 50% excess BMI loss (EBMIL) or experiencing significant weight regain. This systematic review and meta-analysis aimed to compare fasting PYY levels and postprandial area under the curve (AUC) between RYGB responders and non-responders. Methods: Following PRISMA guidelines, PubMed, Embase, and Cochrane databases were searched for observational or interventional studies assessing PYY in adult RYGB patients stratified by weight loss response. Primary outcomes were fasting PYY levels and PYY AUC after standardized meals. Random-effects meta-analysis was conducted using Review Manager 5.4. Mean differences (MD) with 95% confidence intervals (CI) were calculated. Heterogeneity was assessed via Cochran’s Q and I². Results: Five studies were included in the systematic review (92 non-responders and 89 responders), contributing to the fasting PYY meta-analysis, which showed no significant difference between groups (MD 1.71 pg/mL; 95% CI − 5.22 to 8.63; I² = 0%). Four studies reported AUC, also showing no difference (MD 53.16 pg·min/mL; 95% CI − 1726.29 to 1832.61; I² = 0%). Several studies observed lower satiety scores and attenuated appetite suppression in non-responders despite similar PYY profiles. No significant genetic variants in PYY or its receptor were associated with weight loss outcomes. Conclusion: RYGB responders and non-responders have comparable fasting and postprandial PYY concentrations. These findings suggest that differential weight loss after RYGB is likely mediated by factors beyond PYY secretion, including neural, behavioral, or other hormonal mechanisms.
- 19 March 2026
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (4) , 1946-1954
Open AccessHormone PYY does not Explain the Variability in Weight Loss After Roux-en-Y Gastric Bypass: Evidence From a Meta-Analysis.
Background: Peptide YY (PYY) plays a key role in postprandial satiety and is markedly increased after Roux-en-Y gastric bypass (RYGB). While GLP-1 has been widely studied, the role of PYY as a predictor of weight loss success remains unclear. Some patients are considered non-responders, achieving < 50% excess BMI loss (EBMIL) or experiencing significant weight regain. This systematic review and meta-analysis aimed to compare fasting PYY levels and postprandial area under the curve (AUC) between RYGB responders and non-responders. Methods: Following PRISMA guidelines, PubMed, Embase, and Cochrane databases were searched for observational or interventional studies assessing PYY in adult RYGB patients stratified by weight loss response. Primary outcomes were fasting PYY levels and PYY AUC after standardized meals. Random-effects meta-analysis was conducted using Review Manager 5.4. Mean differences (MD) with 95% confidence intervals (CI) were calculated. Heterogeneity was assessed via Cochran’s Q and I². Results: Five studies were included in the systematic review (92 non-responders and 89 responders), contributing to the fasting PYY meta-analysis, which showed no significant difference between groups (MD 1.71 pg/mL; 95% CI − 5.22 to 8.63; I² = 0%). Four studies reported AUC, also showing no difference (MD 53.16 pg·min/mL; 95% CI − 1726.29 to 1832.61; I² = 0%). Several studies observed lower satiety scores and attenuated appetite suppression in non-responders despite similar PYY profiles. No significant genetic variants in PYY or its receptor were associated with weight loss outcomes. Conclusion: RYGB responders and non-responders have comparable fasting and postprandial PYY concentrations. These findings suggest that differential weight loss after RYGB is likely mediated by factors beyond PYY secretion, including neural, behavioral, or other hormonal mechanisms.
- Open Access
- 16 March 2026
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (4) , 1909-1921
Patients with Obesity Undergoing Roux-En-Y Gastric Bypass Versus Fundoplication for Refractory GERD: A Systematic Review and Meta-Analysis
Background: Gastroesophageal reflux disease (GERD) significantly impairs quality of life and is associated with complications such as Barrett’s esophagus and esophageal adenocarcinoma. Obesity exacerbates GERD pathophysiology by elevating intra-abdominal pressure, making treatment more difficult. Current evidence suggests that Roux-en-Y gastric bypass (RYGB) offers superior outcomes compared to fundoplication in patients with severe obesity (BMI ≥ 40 kg/m²). This review aims to critically evaluate fundoplication versus RYGB in the population with obesity and GERD. Methods: We conducted a systematic review and meta-analysis in accordance with PRISMA guidelines. We performed a comprehensive search across PubMed, Embase, and Cochrane databases for studies comparing fundoplication versus RYGB in patients with obesity and GERD. Data extraction was standardized, focusing on intraoperative complications, operative time, length of hospital stay, reoperation, postoperative complications, postoperative dysphagia, and DeMeester score. Statistical analysis was performed using Cochrane RevMan (Review Manager 9.7.1), employing random-effects models. Heterogeneity was assessed using Cochran’s Q test and I² statistic. Results: The analysis included 7 observational studies. We found no differences in complication rates after sensitivity analysis. There were no differences in dysphagia, reoperation rate, operative time and length of stay. At a weighted mean follow-up of 42.3 months (range: 19.6 to 52.0) for fundoplication and 35.2 months (range: 14.6 to 49.0) for RYGB, GERD resolution, measured by the DeMeester score, slightly favored fundoplication, although the absolute difference was not clinically relevant. Regarding weight outcomes, RYGB demonstrated significantly higher total weight loss (TWL) at the 12-month follow-up. Conclusion: Fundoplication appears statistically superior for GERD resolution postoperatively, but the difference is not clinically relevant. RYGB has a higher TWL. Both procedures are safe for GERD control in patients with obesity. The choice between procedures should weigh reflux severity, complication risks, and metabolic diseases associated with obesity. Larger studies are needed to clarify the impact of surgical timing and patient-specific factors.
- 16 March 2026
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (4) , 1909-1921
Open AccessPatients with Obesity Undergoing Roux-En-Y Gastric Bypass Versus Fundoplication for Refractory GERD: A Systematic Review and Meta-Analysis
Background: Gastroesophageal reflux disease (GERD) significantly impairs quality of life and is associated with complications such as Barrett’s esophagus and esophageal adenocarcinoma. Obesity exacerbates GERD pathophysiology by elevating intra-abdominal pressure, making treatment more difficult. Current evidence suggests that Roux-en-Y gastric bypass (RYGB) offers superior outcomes compared to fundoplication in patients with severe obesity (BMI ≥ 40 kg/m²). This review aims to critically evaluate fundoplication versus RYGB in the population with obesity and GERD. Methods: We conducted a systematic review and meta-analysis in accordance with PRISMA guidelines. We performed a comprehensive search across PubMed, Embase, and Cochrane databases for studies comparing fundoplication versus RYGB in patients with obesity and GERD. Data extraction was standardized, focusing on intraoperative complications, operative time, length of hospital stay, reoperation, postoperative complications, postoperative dysphagia, and DeMeester score. Statistical analysis was performed using Cochrane RevMan (Review Manager 9.7.1), employing random-effects models. Heterogeneity was assessed using Cochran’s Q test and I² statistic. Results: The analysis included 7 observational studies. We found no differences in complication rates after sensitivity analysis. There were no differences in dysphagia, reoperation rate, operative time and length of stay. At a weighted mean follow-up of 42.3 months (range: 19.6 to 52.0) for fundoplication and 35.2 months (range: 14.6 to 49.0) for RYGB, GERD resolution, measured by the DeMeester score, slightly favored fundoplication, although the absolute difference was not clinically relevant. Regarding weight outcomes, RYGB demonstrated significantly higher total weight loss (TWL) at the 12-month follow-up. Conclusion: Fundoplication appears statistically superior for GERD resolution postoperatively, but the difference is not clinically relevant. RYGB has a higher TWL. Both procedures are safe for GERD control in patients with obesity. The choice between procedures should weigh reflux severity, complication risks, and metabolic diseases associated with obesity. Larger studies are needed to clarify the impact of surgical timing and patient-specific factors.
- 2 January 2026
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (2) , 848-862
Outcomes of Bariatric Surgery for Idiopathic Intracranial Hypertension: A Systematic Review and a Single-Arm Meta-analysis
Background and Aims Idiopathic intracranial hypertension (IIH) is characterized by elevated intracranial pressure (ICP) in the absence of structural pathology and is strongly linked to obesity. Weight reduction remains the only disease-modifying therapy, and bariatric surgery (BS) may offer durable ICP control and symptom improvement. This study evaluated postoperative clinical, visual, and physiological outcomes in patients with IIH undergoing BS. Methods A systematic review and single-arm meta-analysis were conducted in accordance with PRISMA and Cochrane guidelines. PubMed, Embase, and CENTRAL were searched through April 2025. Eligible studies included obese patients with IIH who underwent any bariatric procedure. Primary outcomes were remission of headache, papilledema, pulsatile tinnitus, and cessation of IIH-related medications. Secondary outcomes included changes in visual parameters, weight loss, BMI reduction, and CSF opening pressure. Risk of bias was assessed with ROBINS-I for observational studies and RoB-2 for randomized trials. Heterogeneity was explored through leave-one-out analyses, Baujat influence plots, and meta-regression. Results Nine studies (eight observational, one randomized clinical trial) comprising 229 patients were included. Patients were predominantly women with severe obesity (BMI 40.4–49.0 kg/m²) and markedly elevated baseline CSF pressures (32–45 cmH₂O). Pooled estimates demonstrated high rates of improvement across outcomes, including headache (84.6%), visual field deficits (83.3%), pulsatile tinnitus (88.7%), and visual symptoms (98.1%). Papilledema resolution approached 98% but showed wide prediction intervals due to small samples and complete-event studies. Medication cessation occurred in 63.3% of patients. CSF pressure decreased significantly (mean − 13.24 cmH₂O), and total weight loss averaged 28.5%, with excess weight loss of 65.7%. Meta-regression indicated that higher baseline CSF pressure and higher proportions of RYGB predicted greater CSF reduction, while preoperative BMI and the proportion of SG significantly moderated postoperative weight loss. Influence diagnostics identified Wills et al. and Lainas et al. as key contributors to heterogeneity in symptom and medication outcomes, and Mollan et al. as the principal driver of variability in weight-loss estimates. Reported complications were infrequent and predominantly mild, and no deaths were noted, although follow-up completeness varied. Risk of bias was low in the randomized trial but moderate to serious in the observational cohorts. Conclusion Bariatric surgery in patients with IIH is associated with favorable postoperative outcomes, including high rates of symptom improvement and reduced medication use. While these findings support the potential disease-modifying role of surgical weight loss, they should be interpreted with caution given the single-arm nature of the available evidence and the predominance of observational studies.
- 2 January 2026
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (2) , 848-862
Outcomes of Bariatric Surgery for Idiopathic Intracranial Hypertension: A Systematic Review and a Single-Arm Meta-analysis
Background and Aims Idiopathic intracranial hypertension (IIH) is characterized by elevated intracranial pressure (ICP) in the absence of structural pathology and is strongly linked to obesity. Weight reduction remains the only disease-modifying therapy, and bariatric surgery (BS) may offer durable ICP control and symptom improvement. This study evaluated postoperative clinical, visual, and physiological outcomes in patients with IIH undergoing BS. Methods A systematic review and single-arm meta-analysis were conducted in accordance with PRISMA and Cochrane guidelines. PubMed, Embase, and CENTRAL were searched through April 2025. Eligible studies included obese patients with IIH who underwent any bariatric procedure. Primary outcomes were remission of headache, papilledema, pulsatile tinnitus, and cessation of IIH-related medications. Secondary outcomes included changes in visual parameters, weight loss, BMI reduction, and CSF opening pressure. Risk of bias was assessed with ROBINS-I for observational studies and RoB-2 for randomized trials. Heterogeneity was explored through leave-one-out analyses, Baujat influence plots, and meta-regression. Results Nine studies (eight observational, one randomized clinical trial) comprising 229 patients were included. Patients were predominantly women with severe obesity (BMI 40.4–49.0 kg/m²) and markedly elevated baseline CSF pressures (32–45 cmH₂O). Pooled estimates demonstrated high rates of improvement across outcomes, including headache (84.6%), visual field deficits (83.3%), pulsatile tinnitus (88.7%), and visual symptoms (98.1%). Papilledema resolution approached 98% but showed wide prediction intervals due to small samples and complete-event studies. Medication cessation occurred in 63.3% of patients. CSF pressure decreased significantly (mean − 13.24 cmH₂O), and total weight loss averaged 28.5%, with excess weight loss of 65.7%. Meta-regression indicated that higher baseline CSF pressure and higher proportions of RYGB predicted greater CSF reduction, while preoperative BMI and the proportion of SG significantly moderated postoperative weight loss. Influence diagnostics identified Wills et al. and Lainas et al. as key contributors to heterogeneity in symptom and medication outcomes, and Mollan et al. as the principal driver of variability in weight-loss estimates. Reported complications were infrequent and predominantly mild, and no deaths were noted, although follow-up completeness varied. Risk of bias was low in the randomized trial but moderate to serious in the observational cohorts. Conclusion Bariatric surgery in patients with IIH is associated with favorable postoperative outcomes, including high rates of symptom improvement and reduced medication use. While these findings support the potential disease-modifying role of surgical weight loss, they should be interpreted with caution given the single-arm nature of the available evidence and the predominance of observational studies.
- 22 September 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 35 (10) , 4520-4530
Efficacy of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy on Hepatic Steatosis and Fibrosis Markers: A Meta-analysis of Randomized Clinical Trials
Metabolic-associated steatotic liver disease (MASLD) and its complications represent a growing global health challenge. Both Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) have demonstrated long-term benefits for liver health and are currently recommended by international guidelines for patients with MASLD who meet surgical criteria. However, few randomized controlled trials (RCTs) have directly compared the hepatic effects of these commonly performed bariatric procedures in this population. A systematic search of PubMed, EMBASE, and Cochrane CENTRAL was conducted to identify RCTs evaluating RYGB and SG in patients with obesity and MASLD, with a minimum follow-up of 12 months. The primary outcome was the change in hepatic fibrosis, assessed by the number of patients with advanced fibrosis postoperatively. Secondary outcomes included changes in liver enzymes and body mass index (BMI). Meta-analyses were performed using Review Manager 5.4 and RStudio 4.1.2. Three RCTs comprising 322 patients (160 undergoing RYGB, 162 undergoing SG) were included. Both procedures significantly reduced the number of patients with advanced fibrosis: SG (OR = 4.10; 95% CI: 2.18–7.69; p < 0.0001) and RYGB (OR = 12.78; 95% CI: 5.21–31.37; p < 0.00001). While RYGB showed a higher overall odds of fibrosis improvement compared to SG (OR = 1.63; 95% CI: 0.94–2.81), this difference was not statistically significant (p = 0.08). No significant differences were found between groups in liver enzyme reductions. Both RYGB and SG significantly improved hepatic fibrosis in patients with MASLD, with RYGB demonstrating a stronger, albeit non-statistically significant, trend toward fibrosis resolution. Both procedures also reduced liver enzyme levels, reinforcing the role of metabolic surgery in improving liver-related outcomes in this population.
- 22 September 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 35 (10) , 4520-4530
Efficacy of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy on Hepatic Steatosis and Fibrosis Markers: A Meta-analysis of Randomized Clinical Trials
Metabolic-associated steatotic liver disease (MASLD) and its complications represent a growing global health challenge. Both Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) have demonstrated long-term benefits for liver health and are currently recommended by international guidelines for patients with MASLD who meet surgical criteria. However, few randomized controlled trials (RCTs) have directly compared the hepatic effects of these commonly performed bariatric procedures in this population. A systematic search of PubMed, EMBASE, and Cochrane CENTRAL was conducted to identify RCTs evaluating RYGB and SG in patients with obesity and MASLD, with a minimum follow-up of 12 months. The primary outcome was the change in hepatic fibrosis, assessed by the number of patients with advanced fibrosis postoperatively. Secondary outcomes included changes in liver enzymes and body mass index (BMI). Meta-analyses were performed using Review Manager 5.4 and RStudio 4.1.2. Three RCTs comprising 322 patients (160 undergoing RYGB, 162 undergoing SG) were included. Both procedures significantly reduced the number of patients with advanced fibrosis: SG (OR = 4.10; 95% CI: 2.18–7.69; p < 0.0001) and RYGB (OR = 12.78; 95% CI: 5.21–31.37; p < 0.00001). While RYGB showed a higher overall odds of fibrosis improvement compared to SG (OR = 1.63; 95% CI: 0.94–2.81), this difference was not statistically significant (p = 0.08). No significant differences were found between groups in liver enzyme reductions. Both RYGB and SG significantly improved hepatic fibrosis in patients with MASLD, with RYGB demonstrating a stronger, albeit non-statistically significant, trend toward fibrosis resolution. Both procedures also reduced liver enzyme levels, reinforcing the role of metabolic surgery in improving liver-related outcomes in this population.
- 3 September 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 35 (10) , 4246-4263
Efficacy and Safety of Bariatric Surgery in Well-Compensated Liver Cirrhosis: A Systematic Review and a Single-Arm Meta-analysis
Introduction The global rise in obesity and liver disease underscores the significance of bariatric and metabolic surgery (BMS) in treating severe obesity and improving liver function. Although liver failure is often considered a contraindication for elective surgeries, the role of bariatric surgery in patients with compensated cirrhosis has been increasingly explored. Methods We systematically searched PubMed, Embase, and Cochrane without temporal restrictions, in January 2025 for randomized controlled trials and observational studies. Statistical analyses were performed using R software. Heterogeneity was assessed with I2 statistics. Results This meta-analysis evaluated BMS's efficacy and safety in patients with cirrhosis by analyzing 26 studies with 22,489 participants. Mortality was 3.33% (95% CI [2.06; 5.35]; I2 = 96.7%). Early postoperative complications were 14.0% (95% CI [7.56; 24.49]; I2 = 90.3%). Patients with cirrhosis had a significant weight loss after 1 year of follow-up (MD -43.06 kg; 95% CI [-70.93; -15.19]; P < 0.0001; I2 = 94.0%), BMI (MD -10.79 kg/m2; 95% CI [-14.45,-7.12]; P < 0.01; I2 = 66.2%), excess weight loss in percentage—EWL% 62.81% (95% CI [52.56; 73.96]; I2 = 78%) and total weight loss in percentage TWL% (26.43% 95% CI [23.89; 28.96]; I2 = 69.3%). The length of stay was 3.77 days ( 95% CI [3.13; 4.42]; I2 = 99.1%). Conclusion Despite increased perioperative risks, mortality remained low, and patients with compensated cirrhosis achieved substantial weight and metabolic improvements, supporting BMS's safety and benefits with proper patient selection.
- 3 September 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 35 (10) , 4246-4263
Efficacy and Safety of Bariatric Surgery in Well-Compensated Liver Cirrhosis: A Systematic Review and a Single-Arm Meta-analysis
Introduction The global rise in obesity and liver disease underscores the significance of bariatric and metabolic surgery (BMS) in treating severe obesity and improving liver function. Although liver failure is often considered a contraindication for elective surgeries, the role of bariatric surgery in patients with compensated cirrhosis has been increasingly explored. Methods We systematically searched PubMed, Embase, and Cochrane without temporal restrictions, in January 2025 for randomized controlled trials and observational studies. Statistical analyses were performed using R software. Heterogeneity was assessed with I2 statistics. Results This meta-analysis evaluated BMS's efficacy and safety in patients with cirrhosis by analyzing 26 studies with 22,489 participants. Mortality was 3.33% (95% CI [2.06; 5.35]; I2 = 96.7%). Early postoperative complications were 14.0% (95% CI [7.56; 24.49]; I2 = 90.3%). Patients with cirrhosis had a significant weight loss after 1 year of follow-up (MD -43.06 kg; 95% CI [-70.93; -15.19]; P < 0.0001; I2 = 94.0%), BMI (MD -10.79 kg/m2; 95% CI [-14.45,-7.12]; P < 0.01; I2 = 66.2%), excess weight loss in percentage—EWL% 62.81% (95% CI [52.56; 73.96]; I2 = 78%) and total weight loss in percentage TWL% (26.43% 95% CI [23.89; 28.96]; I2 = 69.3%). The length of stay was 3.77 days ( 95% CI [3.13; 4.42]; I2 = 99.1%). Conclusion Despite increased perioperative risks, mortality remained low, and patients with compensated cirrhosis achieved substantial weight and metabolic improvements, supporting BMS's safety and benefits with proper patient selection.